Plasma levels of tissue-type plasminogen activator (t-PA) were increased in the SVT MPN+ and SVT MPN− cohorts compared with the control group, with median levels of 2.77 vs. <1.71 ng/mL (p = 7.3 × 10−4) and 2.59 vs. <1.71 ng/mL (p = 2.5 × 10−4) but did not differ between the two patient groups (Table 2, Figure 2E). This evidence concerns the gene PLAT and myeloproliferative disorder.